2022 World Conference on Lung Cancer (ePosters)-EP13.01-013. Determination of the Timing of Bevacizumab Administration in Osimertinib and Bevacizumab Combination Therapy

EP13.01-013. Determination of the Timing of Bevacizumab Administration in Osimertinib and Bevacizumab Combination Therapy

Back to course

Pdf Summary

A study was conducted to determine the optimal timing of administering bevacizumab in combination with osimertinib, a treatment for metastatic EGFR-mutant lung cancers. A total of 31 patients were enrolled in the study and received osimertinib daily at a dose of 80 mg, while bevacizumab was administered by drip infusion on the first day of each cycle. The patients were divided into two treatment groups: "T to AT" (osimertinib followed by bevacizumab) and "AT" (bevacizumab alone). The results showed that the "T to AT" treatment modality was more effective and prolonged drug resistance compared to the "AT" modality. Patients with EGFR19 mutations had a better prognosis than those with EGFR21 mutations, regardless of the treatment modality. The baseline characteristics of the patients were also analyzed, including age, sex, smoking status, genotypes, metastases, and treatment history. At the data cutoff date, the median duration of follow-up was 14.5 months. Response analysis showed that 23.08% of patients had a partial response, 72.92% had stable disease, and none had progressive disease. The median progression-free survival was 13.47 months. The study concluded that the timing of bevacizumab administration in combination with osimertinib is important for optimizing treatment outcomes in metastatic EGFR-mutant lung cancers. The "T to AT" treatment modality and EGFR19 mutations were associated with better treatment outcomes. Further research is needed to validate these findings and explore the underlying mechanisms.

Asset Subtitle

Fei Teng

Meta Tag

Speaker Fei Teng

Topic Pulmonology, Radiology, and Staging

Keywords

bevacizumab

osimertinib

metastatic EGFR-mutant lung cancers

timing of administration

treatment modality

EGFR19 mutations

EGFR21 mutations

baseline characteristics

progression-free survival

underlying mechanisms